Cargando…
Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes
Purpose: It has been reported that dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have a role in modulation of inflammation associated with coronavirus disease 2019 (COVID-19). This study asses...
Autores principales: | Foresta, Andreana, Ojeda-Fernandez, Luisa, Macaluso, Giulia, Roncaglioni, Maria Carla, Tettamanti, Mauro, Fortino, Ida, Leoni, Olivia, Genovese, Stefano, Baviera, Marta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974363/ https://www.ncbi.nlm.nih.gov/pubmed/36933975 http://dx.doi.org/10.1016/j.clinthera.2023.02.007 |
Ejemplares similares
-
Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
por: Baviera, Marta, et al.
Publicado: (2022) -
Impact of first and second/third wave of COVID-19 pandemic on post-acute cardiovascular outcomes in Lombardy
por: Ojeda-Fernández, Luisa, et al.
Publicado: (2023) -
Diabetes mellitus duration and mortality in patients hospitalized with acute myocardial infarction
por: Baviera, Marta, et al.
Publicado: (2022) -
Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents
por: Mousa, Shaker A., et al.
Publicado: (2019) -
Combined effect of sodium–glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease
por: Araki, Shin‐ichi
Publicado: (2019)